Compare FRO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRO | DNTH |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 1995 | 2018 |
| Metric | FRO | DNTH |
|---|---|---|
| Price | $40.90 | $82.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $37.67 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 3.3M | 926.4K |
| Earning Date | 05-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.48 |
| P/E Ratio | $34.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.25 | $18.08 |
| 52 Week High | $40.74 | $96.50 |
| Indicator | FRO | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 69.80 | 48.32 |
| Support Level | $33.68 | $79.27 |
| Resistance Level | N/A | $92.41 |
| Average True Range (ATR) | 1.61 | 5.51 |
| MACD | 0.55 | -0.15 |
| Stochastic Oscillator | 99.16 | 57.80 |
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.